Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49.6M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
6.69M
-
Shares change
-
+429K
-
Total reported value, excl. options
-
$46.4M
-
Value change
-
+$3.07M
-
Put/Call ratio
-
1.2
-
Number of buys
-
29
-
Number of sells
-
-18
-
Price
-
$6.93
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q3 2024
64 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q3 2024.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.69M shares
of 49.6M outstanding shares and own 13.49% of the company stock.
Largest 10 shareholders include Northpond Ventures, LLC (1.94M shares), BlackRock, Inc. (1.13M shares), VANGUARD GROUP INC (946K shares), STATE STREET CORP (492K shares), GEODE CAPITAL MANAGEMENT, LLC (449K shares), Sands Capital Ventures, LLC (406K shares), Halter Ferguson Financial Inc. (305K shares), NORTHERN TRUST CORP (159K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (135K shares), and BRIDGEWAY CAPITAL MANAGEMENT, LLC (80.6K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.